These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28111882)

  • 21. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between PD-1/PD-L1 and T regulate cells in early recurrent miscarriage.
    Li G; Lu C; Gao J; Wang X; Wu H; Lee C; Xing B; Zhang Q
    Int J Clin Exp Pathol; 2015; 8(6):6512-8. PubMed ID: 26261529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.
    Dilly AK; Song X; Zeh HJ; Guo ZS; Lee YJ; Bartlett DL; Choudry HA
    Transl Res; 2015 Oct; 166(4):344-54. PubMed ID: 25890193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
    Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
    Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
    Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
    Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].
    Shi MH; Xing YF; Zhang ZL; Huang JA; Chen YJ
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):85-8. PubMed ID: 23714659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
    Ansell SM
    J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
    Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
    Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells.
    Kim JH; Choi YJ; Lee BH; Song MY; Ban CY; Kim J; Park J; Kim SE; Kim TG; Park SH; Kim HP; Sung YC; Kim SC; Shin EC
    J Allergy Clin Immunol; 2016 May; 137(5):1466-1476.e3. PubMed ID: 26824999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular cloning and expression analysis of the canine chemokine receptor CCR9.
    Maeda S; Ohno K; Tsukamoto A; Nakashima K; Fukushima K; Goto-Koshino Y; Fujino Y; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jan; 145(1-2):534-9. PubMed ID: 22209203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed death-1
    Singh A; Mohan A; Dey AB; Mitra DK
    Clin Exp Immunol; 2017 Feb; 187(2):269-283. PubMed ID: 27665733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.
    Baban B; Liu JY; Qin X; Weintraub NL; Mozaffari MS
    PLoS One; 2015; 10(4):e0124059. PubMed ID: 25902191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
    Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
    Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
    Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
    Xerri L; Chetaille B; Serriari N; Attias C; Guillaume Y; Arnoulet C; Olive D
    Hum Pathol; 2008 Jul; 39(7):1050-8. PubMed ID: 18479731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
    Vincent-Fabert C; Roland L; Zimber-Strobl U; Feuillard J; Faumont N
    Cell Commun Signal; 2019 Aug; 17(1):89. PubMed ID: 31382969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transferrin receptor expression in canine lymphoma.
    Priest H; McDonough S; Erb H; Daddona J; Stokol T
    Vet Pathol; 2011 Mar; 48(2):466-74. PubMed ID: 20685917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor effects of perphenazine on canine lymphoma.
    Tsuji S; Yabe R; Usui T; Mizuno T; Ohama T; Sato K
    J Vet Med Sci; 2016 Sep; 78(8):1293-8. PubMed ID: 27150024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.